Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS (sotorasib), a KRASG12C...
INGELHEIM, Germany--(BUSINESS WIRE)--Sep 16, 2021-- |!| Oelwein
INGELHEIM, Germany--(BUSINESS WIRE)--Sep 16, 2021-- |!| Oelwein